Recently, the interest has focused on the increased prevalence of thrombophilic defects in women with gestational complications.
To explore whether women with early recurrent pregnancy loss (RPL) are at increased risk of being carriers of the Factor V Leiden (FVL) mutation compared to those who have a normal reproductive history.
A manual and electronic literature search was undertaken to identify studies with a case–control population of women with two or more first trimester RPLs of undetermined origin and age- and ethnicity-matched control group with normal reproductive history and at least one full-term delivery. Both groups were screened for FVL mutation. A quality assessment was performed according to the pre-established validity criteria and using the Cochrane handbook guidelines for observational studies. The combinability of studies was assessed by clinical and statistical methods (Breslow–Day’s test of homogeneity). Quantitative data were abstracted with regard to the prevalence of FVL mutation in the case and control group, and 2 × 2 tables were created. The ratio comparing the odds of FVL mutation in women with early RPL with the odds of FVL mutation in women with normal reproductive outcome was calculated with its 95 % confidence interval (CI) by Mantel–Haenszel method.
Nine studies met the inclusion criteria and were selected for review. A total of 2,147 women were screened for the FVL mutation, 1,305 women with early RPL, and 842 women with no gestational complications. Women with early RPL had indeed a statistically significantly increased carrier frequency of FVL mutation, the common OR being 1.68 (95 % CI: 1.16–2.44).
FVL carrier state may increase the susceptibility for early RPL. Testing for FVL mutation should be considered in women with unexplained early RPL and thrombophylaxis has been suggested in women with unexplained RPL associated with FVL mutation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Factor V Leiden
Recurrent pregnancy loss
Activated protein C
Younis JS, Ohel G, Brenner B, Ben-Ami M (1997) Familial thrombophilia—the scientific rationale for thrombophylaxis in recurrent pregnancy loss? Hum Reprod 12:1389–1390
Cook CL, Pridham DD (1995) Recurrent pregnancy loss. Curr Opin Obstet Gynecol 7:357–366
Clifford K, Rai R, Watson H, Regan L (1994) An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod 9:1328–1332
Kutteh WH, Park VM, Deitscher SR (1999) Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 71:1048–1053
Haywood L, Brown MD (1991) Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 34:1–17
Blumenfeld Z, Weiner Z, Lorber M, Sujov P, Thaler I (1991) Anticardiolipin antibodies in patients with recurrent pregnancy wastage: treatment and uterine blood flow. Obstet Gynecol 78:584–589
Kamashta MA (1998) Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 7(Suppl 2):S162–S165
Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A (1996) The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 75:387–388
Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J (1996) Increased fetal loss in women with heritable thrombophilia. Lancet 348:913–916
Meinardi JR, Middeldorp S, Kam PJ, Koopman MMW, van Pampus ECM, Hamulyak K (1999) Increased risk of fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 130:736–739
Tormen D, Simioni P, Prandoni P, Luni S, Innella B, Sabbion P et al (1999) The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Hamost 82:1237–1239
Dahlback B, Carlsson M, Svensoon PJ (1993) Familial thrombophilia due to a previously recognized mechanism characterised by poor anticoagulant response to activated protein C. Proc Natl Acad Sci 90:1004–1008
Bertina RM, Koeleman BPC, Koster T (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67
Dahlback B (1995) Molecular genetics of thrombophilia factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Clin Lab Med 125:566–571
Dahlback B (1994) Physiological anticoagulation: resistance activated protein C and venous thromboembolism. J Clin Invest 94:923–927
Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conrad J et al (1997) A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89:397–402
Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346:1133–1134
Chan LC, Bourke C, Lam CK, Liu HW, Brookes S, Jenkins Y et al (1996) Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors: correlation with absence of Arg 506-Gln mutation of factor V gene. Thromb Haemost 75:522–523
Griffin JH, Evart B, Wideman C, Fernandez JA (1993) Antocoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82:1989–1994
Svensson PJ, Dahlback B (1994) Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517–522
Hellgren M, Svensson PJ, Dahlback B (1995) Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 173:210–213
Vanderbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR (1994) Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leide mutation. Lancet 344:1453–1457
Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:2008–2012
Khan K, Riet GT, Glanville J et al (2000) Undertaking systematic reviews of research on effectiveness. CRD’s guidance for carrying out or commissioning reviews, 2nd edn. NHS Centre for Reviews and Dissemination, University of York, York
Formulating the problem. In: Alderson P, Green S, Higgins JPT (eds) [Cochrane Reviewer’s Handbook 4.2.2 ed]. Available at http://www.cochrane.org/resources/handbook/hbook.htm
Zoller B, Sevensson PJ, He X, Dahlback B (1994) Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521–2524
Ridger PM, Miletich JP, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. J Am Med Assoc 277:1305–1307
Bauer KA (1995) Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Throm Haemost 74:94–100
Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rogenhofer N, Hasbargen U, Hiller E, Thaler C (2001) Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 46:124–131
Rai R, Regan L, Hadley E (1996) Second trimester pregnancy loss is associated with activate C resistance. Br J Haematol 92:489–490
Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G et al (1997) Activated protein C resistance can be associated with recurrent pregnancy loss. Br J Haematol 97:551–554
Metz J, Kloss M, O’ Malley CJ et al (1997) Prevalence of Factor V Leiden is not increased in women with recurrent miscarriage. Clin Appl Thromb Hemost 3:137–140
Ridker PM, Miletich JP, Buring JE, Ariyo A et al (1998) Factor V Leiden as a risk factor for recurrent pregnancy loss. Ann Intern Med 128:1000–1003
Souza SS, Ferriani RA, Pontes AG, Zago MA, Franco RF (1999) Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion. Hum Reprod 14(10):2448–2450
Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D (1999) A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 14(6):1624–1627
Wramsby ML, Sten-Linder M, Bremme K (2000) Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril 74(5):987–991
Sarig G, Younis JS, Hoffman R, Lanir N, Blumenfeld Z, Brenner B (2002) Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 77(2):342–347
Younis JS, Ohel G, Brenner B, Haddad S, Lanir N, Ben-Ami M (2000) The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation. Br J Obst Gyn 107:415–419
Rai R, Backos M, Elgaddal S, Shlebak A, Regan L (2002) Factor V Leiden and recurrent miscarriage—prospective outcome of untreated pregnancies. Hum Reprod 17(2):442–445
Hashimoto K, Shizusawa Shimoya K, Ohashi K, Shimizu T et al (1999) The factor V Leiden mutation in Japanese couples with recurrent abortion. Hum Reprod 14(7):1872–1874
Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV et al (2000) Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 343:1015–1018
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
Breslow NE, Day NE (1980) Statistical methods in cancer research. Vol 1. The analysis of case–control studies. IARC Sci Publ 32:335–338
Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple graphical test. BMJ 315:629–634
Balasch J, Reverter JC, Fabregues F, Tassies D, Rafel M, Creus M (1997) Vanrell JA First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 12(5):1094–1097
Grandone E, Margaglione M, Colaizzo D et al (1997) Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 77:822–824
Dizon-Townson DS, Kinney S, Branch DW, Ward K (1997) The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 34:217–223
Pauer HU, Neesen J, Hinney B (1998) Factor V Leiden and its relevance in patients with recurrent abortions. Am J Obstet Gynecol 178:629
Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M (2000) Activated protein C resistance and factor V Leiden mutation can be associated with first- as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 43:31–35
Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A et al (2000) Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 15(2):458–462
Rai R, Shlebak A, Cohen H, Backos M, Holmes Z et al (2001) Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 16(5):961–965
Reznikoff-Etievant MF, Cayol V, Carbonne B, Robert A, Coulet F (2001) Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. Br J Obstet Gynaecol 108:1251–1254
Sackett D, Haynes BR, Guyatt GH, Tugwell P Deciding whether your treatment has done harm in clinical epidemiology: a basic science for clinical medicine. 2nd edition, Little, Brown and Company, pp 285
Seligsohn U, Zivelin A (1997) Thrombophilia as multigenic disorder. Thromb Haemost 78:297–301
Clark P, Brennand J, Conkie JA (1998) Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Throm Haemost 79:1166–1170
Cumming AM, Tait RC, Fildes S (1995) Development of resistance to activated protein C during pregnancy. Brit J Haematol 90:725–727
Burton GJ, Jauniaux E, Watson AL (1999) Maternal arterial connections to the placental intervillous space during the first trimester of human pregnancy: the Boyd collection revisited. Am J Obstet Gynecol 181:718–724
Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K (1997) Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 177:402–405
Mousa HA, Alfirevic Z (2000) Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 15:1830–1833
Rai R (2000) Obstetric management of antiphospholipid antibody syndrome. J Autoimmun 15:203–207
Rai R, Cohen H, Dawe M, Regan L (1997) Randomized controlled trial of aspirin plus heparin in pregnant women with recurrent miscarriage associated with antiphospholipid antibodies. BMJ 314:253–257
Ioannidis JP, Haidich AB, Pappa M et al (2001) Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286:821–830
McKee M, Britton A, Black N et al (1999) Methods in health services research. Interpreting the evidence: choosing between randomized and nonrandomized studies. BMJ 319:312–315
Kunz R, Oxman AD (1998) The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 317:1185–1190
Egger M, Davey Smith G, Schneider M (2001) Systematic reviews of observational studies. In: Egger M, Davey Smith G, Altman D (eds.) BMJ Publishing Group, London pp 211–227
Moher D, Fortin P, Jadad AR et al (1996) Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet 347:363–366
Berlin JA, Miles CG, Cirigliano MD, et al. (1997) Does blinding of readers affect the results of meta-analyses? Results of a randomized trial. Online J Current Clin Trials (Doc no 205)
CS re-addressed specific questions, discussed in detail data, analysis, and results, and wrote the final draft of the manuscript. TAJ conceived the study, designed the study, analyzed data and results, and wrote the first draft of the manuscript. MW conceived the study and reviewed the paper. We are very grateful to the Saudi Cultural Bureau, Ottawa, ON, for the support of Dr. Al-Jishi.
Conflict of interest
The authors declare that they have no conflict of interest.
The manuscript does not contain clinical studies or patient data.
About this article
Cite this article
Sergi, C., Al Jishi, T. & Walker, M. Factor V Leiden mutation in women with early recurrent pregnancy loss: a meta-analysis and systematic review of the causal association. Arch Gynecol Obstet 291, 671–679 (2015). https://doi.org/10.1007/s00404-014-3443-x
- Factor V Leiden
- Recurrent pregnancy loss
- Recurrent spontaneous abortions
- First trimester
- Coagulation defects